As the United States grapples with an unprecedented shortage of semaglutide-based diabetes and weight-loss drugs, Canada has quietly secured a stable supply of a generic version. The divergence underscores a broader systemic failure in pharmaceutical distribution and pricing, with implications for millions of patients on both sides of the border.
Last week, Health Canada approved the first generic version of semaglutide, the active ingredient in Novo Nordisk’s blockbuster drugs Ozempic and Wegovy. The announcement came as a relief for Canadian patients, many of whom had faced intermittent shortages since 2022 due to global demand spikes. Canadian officials negotiated a guaranteed supply agreement with the manufacturer, ensuring that domestic patients will not face the same level of scarcity seen in the US.
Across the border, the situation is dire. The US Food and Drug Administration’s drug shortage database lists both Ozempic and Wegovy as in shortage, with no immediate resolution in sight. Demand has surged beyond manufacturing capacity, driven by off-label use for weight loss and compounding pharmacies exploiting regulatory loopholes. Patients with type 2 diabetes, who rely on the drug for glycaemic control, are forced to ration doses or switch to less effective alternatives.
The contrast highlights two different approaches to pharmaceutical regulation. Canada’s single-payer system allows for bulk purchasing and price negotiation, while the US fragmented insurance system creates a patchwork of access. Generic entry in Canada was facilitated by the Patented Medicine Prices Review Board, which can compel manufacturers to license generics if prices are deemed excessive. In the US, patent protections and market exclusivity delay generic competition for years.
This is not a story of ideological victory but of practical consequence. The physical reality is that semaglutide molecules are identical regardless of packaging. Yet their availability varies dramatically based on policy decisions. Canada’s supply security comes at a cost: the generic will be priced 30 per cent below the brand version, but still higher than what many US patients pay with insurance discounts. For the uninsured, Canadian prices remain out of reach.
Meanwhile, the biosphere continues its silent collapse. Climate change exacerbates metabolic disorders, increasing the population that needs these drugs. Wildfire smoke and heatwaves worsen diabetes outcomes. Yet we divert our attention to the logistics of drug distribution rather than addressing root causes: an ultra-processed food environment and a sedentary culture.
Technological solutions exist. Continuous glucose monitors, AI-driven dietary apps, and urban design that encourages walking could reduce dependency on pharmaceuticals. But these require systemic investment, not just corporate profit motives.
The lesson from Canada’s drug supply is clear: cartography of crisis can be redrawn when political will aligns with public health. For now, Canadian patients can breathe easier. But the real emergency, the entropy of planetary systems, remains unsolved.
